Chemotherapy News and Research

Latest Chemotherapy News and Research

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results.

1 Apr 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

International scientists identify novel genetic defects that induce oesophageal cancer

A team of scientists from the Cancer Science Institute of Singapore at the National University of Singapore and National University Cancer Institute Singapore, and their collaborators from the Cedars-Sinai Medical Centre, UCLA School of Medicine, demonstrated that a number of novel genetic defects are able to induce oesophageal cancer.

31 Mar 2014

New -7 million centre to lead research in manufacturing advanced chemical products

A new -7 million centre at the University of Leeds will lead UK research in manufacturing advanced chemical products. The Centre for Doctoral Training (CDT) in Complex Particulate Products and Processes will fund 50 new research students in a field that has been targeted by the Government as a key growth area for the UK economy.

29 Mar 2014

Physicians suspect that chemotherapy can accelerate aging process

Physicians have long suspected that chemotherapy can accelerate the aging process in patients treated for cancer. Using a test developed at UNC Lineberger Comprehensive Cancer Center to determine molecular aging, UNC oncologists have directly measured the impact of anti-cancer chemotherapy drugs on biological aging.

29 Mar 2014

Research findings offer insight into helping cancer patients assess treatment risk

UT Southwestern Medical Center researchers are developing a new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.

28 Mar 2014

Researchers identify plant compounds that may support delivery of chemotherapy treatments

Researchers at Plant & Food Research have identified plant compounds present in carrots and parsley that may one day support more effective delivery of chemotherapy treatments.

28 Mar 2014

Study: Sexual dysfunction common with lung cancer

Many lung cancer patients suffer difficulties with sexual expression and intimacy, yet for too long the topic has been ignored by doctors and researchers, experts have said at the 4th European Lung Cancer Conference (ELCC).

28 Mar 2014

Scientists move a step closer to preserving fertility in young boys with cancer

Scientists have moved a step closer to being able to preserve fertility in young boys who undergo chemotherapy and radiation treatments for cancer. The new research, published in Fertility and Sterility, the journal of the American Society for Reproductive Medicine, addresses the safety of an option scientists are developing for boys who aren't sexually mature and cannot bank sperm.

28 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy - delivered directly through a tumor's blood supply - is working.

27 Mar 2014

Quarter of breast cancer survivors are worse off financially due to treatment

Four years after being treated for breast cancer, a quarter of survivors say they are worse off financially, at least partly because of their treatment, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.

27 Mar 2014

EORTC study does not support combination chemotherapy for soft tissue sarcoma

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.

27 Mar 2014

Journal addresses impact of obesity on gynecologic cancer patients

Latest special issue of journal Gynecologic Oncology addresses the impact of obesity on gynecologic cancer patients, oncologists and cancer care delivery systems

26 Mar 2014

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

26 Mar 2014

Vigilant announces completion of $2 million oversubscribed Series A financing

Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.

25 Mar 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

International scientists identify novel genetic defects that induce oesophageal cancer

New -7 million centre to lead research in manufacturing advanced chemical products

Physicians suspect that chemotherapy can accelerate aging process

Research findings offer insight into helping cancer patients assess treatment risk

Researchers identify plant compounds that may support delivery of chemotherapy treatments

Study: Sexual dysfunction common with lung cancer

Scientists move a step closer to preserving fertility in young boys with cancer

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Cytrx releases statement in response to two recent lawsuits

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

Quarter of breast cancer survivors are worse off financially due to treatment

EORTC study does not support combination chemotherapy for soft tissue sarcoma

Journal addresses impact of obesity on gynecologic cancer patients

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

Vigilant announces completion of $2 million oversubscribed Series A financing

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in